KYNTRA BIO, INC. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Kyntra Bio reduced its royalty financing obligation with NQ Project Phoebus from $125M to $65M (including $42.6M accelerated payment in August 2026), leaving only $15M in future payments capped at 50% of roxadustat revenues from Astellas territories. The company discontinued FG-3246 and FG-3180 after Phase 2 interim analysis showed insufficient efficacy, saving >$20M in operating expenses over 2027–2028. Cash position of $44.1M (cash, equivalents, investments, accounts receivable as of Sept 30, 2026) funds operations into 2028; pivotal Phase 3 roxadustat trial in LR-MDS planned Q1 2027, contingent on partnership or capital raise.
Why this rating
Debt reduction meaningful relative to $21M market cap; major expense cuts support survival. Roxadustat focus is strategic. However, Phase 3 contingent on external capital or deal—critical execution risk remains.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-27.1% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $3.10 ▲ 33.05% | at our read · unknown $2.33 | +10 min · unknown $2.15 ▼ 7.73% | +30 min · unknown $2.20 ▼ 5.58% | +1 hr · unknown $2.15 ▼ 7.60% | +4 hrs · unknown $2.07 ▼ 11.16% |
The stock had already moved -24.84% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.